

# Aldo Prawira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9295209/publications.pdf>

Version: 2024-02-01

7  
papers

52  
citations

1684188

5  
h-index

1720034

7  
g-index

9  
all docs

9  
docs citations

9  
times ranked

55  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 608-620.	3.9	11
2	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. <i>Molecular Imaging and Biology</i> , 2021, 23, 70-83.	2.6	1
3	Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2955-2968.	2.5	6
4	Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 1236-1246.	4.2	6
5	FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1857-1868.	7.7	13
6	Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9405.	4.1	9
7	Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 872.	3.7	6